Showing 1 - 10 of 35 records.

131-I-MIBG Expanded Access: An Open Label, Expanded Access Protocol Using I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma

  • Conditions: Adult Studies, Cancer - Neuroblastoma
  • Gender: Female, Male

Provide palliative therapy with MIBG for patients with advanced neuroblastoma Gain more information about acute and late toxicity of 131I-MIBG therapy for patients with refractory neuroblastoma ...More

20110261-TVEC: A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non Central Nervous System Tumors That are Amenable to Direct Injection

  • Conditions: Cancer - Kidney Tumors, Cancer - Liver Tumors, Cancer - Neuroblastoma, Cancer - Musculoskeletal Tumors, Neuroblastoma Relapse - Refractory, Sarcoma Osteosarcoma Relapse, Sarcoma Ewing Relapse, Sarcoma Rhabdomyosarcoma Relapse, Brain Spinal Neurofibromatosis Sarcoma MPNST Relapse, Liver Relapse - Refractory, Kidney Relapse - Refractory, Solid Tumor Retinoblastoma Relapse - Refractory, Solid Tumor Neurofibromatosis Sarcoma MPNST Relapse - Refractory, Solid Tumor Melanoma Relapse - Refractory, Solid Tumor Germ Cell Tumor Relapse - Refractory, Solid Tumors - All Other

PURPOSE: This is a phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection.
 DETAILED DESCRIPTION: This is a phase 1, multicenter, open-label study of talimogene ...More

ADVL1011: A Phase I Study of JAK Inhibition (INCB018424) in Children With Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Hemangioma and Vascular Malformation, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Retinoblastoma
  • Gender: Female, Male

This phase I clinical trial is studying the side effects and best dose of INCB18424 in treating young patients with relapsed or refractory solid tumor, leukemia, or myeloproliferative disease.  ...More

ADVL1111: A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND# 112603) in Children With Relapsed or Refractory Solid Tumors

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Neurofibromatosis Tumors, Cancer - Retinoblastoma
  • Gender: Female, Male

This phase I trial studies the side effects and best dose of tivantinib in treating younger patients with relapsed or refractory solid tumors. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. ...More

ADVL1312: A Phase 1/2 Study of MK-1775 in Combination With Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Retinoblastoma, Brain Spinal Tumors Medulloblastoma Relapse, Brain Spinal Tumor Low Grade Glioma Relapse, Brain Spinal Tumor DIPG Relapse, Brain and Spinal Tumor Ependymoma Relapse, Brain Spinal Neurofibromatosis Sarcoma MPNST Relapse, Brain Spinal Other ATRT, Brain Spinal Other Craniopharyngioma, Brain Spinal Other Germ Cell Tumor, Brain Spinal Other Choroid Plexus Tumor, Brain Spinal Other All Other, Sarcoma Ewing Relapse, Sarcoma Osteosarcoma Relapse, Sarcoma Rhabdomyosarcoma Relapse, Neuroblastoma Relapse - Refractory, Liver Relapse - Refractory, Kidney Relapse - Refractory, Solid Tumor Retinoblastoma Relapse - Refractory, Solid Tumor Neurofibromatosis Sarcoma MPNST Relapse - Refractory, Solid Tumor Melanoma Relapse - Refractory, Solid Tumor Germ Cell Tumor Relapse - Refractory, Solid Tumors - All Other

This phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan hydrochloride may stop the grow ...More

ADVL1322: A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid Tumors

  • Conditions: Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Brain Spinal Neurofibromatosis Sarcoma MPNST Relapse, Sarcoma Osteosarcoma Relapse, Sarcoma Ewing Relapse, Sarcoma Rhabdomyosarcoma Relapse, Neuroblastoma Relapse - Refractory, Liver Relapse - Refractory, Solid Tumor Neurofibromatosis Sarcoma MPNST Relapse - Refractory

PURPOSE: The purpose of this study is to find out what effects, good or bad, pazopanib (GW786034), National Service Center (NSC) # 737754, has on children, adolescents and young adults between 12 months and less than or equal to 18 years of age with relapsed or refractory rhabdomyosarcoma, no ...More

ADVL1414: A Phase 1 Study of Selinexor (KPT-330, IND#125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors.

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Leukemia and Lymphoma, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Lymphoma Hodgkin Relapse, Lymphoma Non Hodgkin Relapse, Brain Spinal Tumors Medulloblastoma Relapse, Brain Spinal Tumor Low Grade Glioma Relapse, Brain Spinal Tumor DIPG Relapse, Brain and Spinal Tumor Ependymoma Relapse, Brain Spinal Neurofibromatosis Sarcoma MPNST Relapse, Brain Spinal Neurofibromatosis OPG, Brain Spinal Other Germ Cell Tumor, Brain Spinal Other Choroid Plexus Tumor, Brain Spinal Other Craniopharyngioma, Brain Spinal Other ATRT, Brain Spinal Other All Other, Sarcoma Osteosarcoma Relapse, Sarcoma Ewing Relapse, Sarcoma Rhabdomyosarcoma Relapse, Neuroblastoma Relapse - Refractory, Liver Relapse - Refractory, Kidney Relapse - Refractory, Solid Tumor Retinoblastoma Relapse - Refractory, Solid Tumor Neurofibromatosis Sarcoma MPNST Relapse - Refractory, Solid Tumor Neurofibromatosis OPG Low Grade Glioma, Solid Tumor Melanoma Relapse - Refractory, Solid Tumor Germ Cell Tumor Relapse - Refractory, Solid Tumors - All Other

PURPOSE: The investigators will conduct a phase 1 trial of Selinexor in children with recurrent or refractory solid tumors, including CNS tumors using the Rolling Six design. The aims of the trial will be to establish the maximum tolerated pediatric doses of tablet formulation; to investigate ...More

ADVL1513: A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Leukemia and Lymphoma, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Retinoblastoma, Lymphoma Hodgkin Relapse, Lymphoma Non Hodgkin Relapse, Brain Spinal Tumors Medulloblastoma Relapse, Brain Spinal Tumor DIPG Relapse, Brain Spinal Tumor Low Grade Glioma Relapse, Brain and Spinal Tumor Ependymoma Relapse, Brain Spinal Neurofibromatosis Sarcoma MPNST Relapse, Brain Spinal Neurofibromatosis OPG, Sarcoma Ewing Relapse, Sarcoma Osteosarcoma Relapse, Sarcoma Rhabdomyosarcoma Relapse, Brain Spinal Other Choroid Plexus Tumor, Brain Spinal Other Germ Cell Tumor, Brain Spinal Other ATRT, Brain Spinal Other Craniopharyngioma, Brain Spinal Other All Other, Neuroblastoma Relapse - Refractory, Liver Relapse - Refractory, Kidney Relapse - Refractory, Solid Tumor Retinoblastoma Relapse - Refractory, Solid Tumor Neurofibromatosis Sarcoma MPNST Relapse - Refractory, Solid Tumor Neurofibromatosis OPG Low Grade Glioma, Solid Tumor Melanoma Relapse - Refractory, Solid Tumor Germ Cell Tumor Relapse - Refractory, Solid Tumors - All Other

PURPOSE: This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells. DETAILED D ...More

ADVL1514: A Phase 1 study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan

  • Conditions: Cancer - Leukemia and Lymphoma, Cancer - Brain and Spinal Tumors, Cancer - Kidney Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Cancer - Liver Tumors, Brain Spinal Tumors Medulloblastoma Relapse, Brain Spinal Tumor Low Grade Glioma Relapse, Brain Spinal Tumor DIPG Relapse, Brain and Spinal Tumor Ependymoma Relapse, Brain Spinal Neurofibromatosis Sarcoma MPNST Relapse, Sarcoma Ewing Relapse, Sarcoma Osteosarcoma Relapse, Sarcoma Rhabdomyosarcoma Relapse, Brain Spinal Neurofibromatosis OPG, Brain Spinal Other Germ Cell Tumor, Brain Spinal Other Choroid Plexus Tumor, Brain Spinal Other Craniopharyngioma, Brain Spinal Other ATRT, Brain Spinal Other All Other, Neuroblastoma Relapse - Refractory, Liver Relapse - Refractory, Kidney Relapse - Refractory, Solid Tumors - All Other, Solid Tumor Retinoblastoma Relapse - Refractory, Solid Tumor Neurofibromatosis Sarcoma MPNST Relapse - Refractory, Solid Tumor Neurofibromatosis OPG Low Grade Glioma, Solid Tumor Melanoma Relapse - Refractory, Solid Tumor Germ Cell Tumor Relapse - Refractory

PURPOSE: This phase I trial studies the side effects and best dose of nanoparticle albumin-bound rapamycin when given together with temozolomide and irinotecan hydrochloride in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not ...More

ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors

  • Conditions: Cancer - Brain and Spinal Tumors, Cancer - Liver Tumors, Cancer - Musculoskeletal Tumors, Cancer - Neuroblastoma, Brain Spinal Tumors Medulloblastoma Relapse, Brain Spinal Tumor Low Grade Glioma Relapse, Brain Spinal Tumor DIPG Relapse, Brain and Spinal Tumor Ependymoma Relapse, Brain Spinal Neurofibromatosis Sarcoma MPNST Relapse, Brain Spinal Neurofibromatosis OPG, Brain Spinal Other ATRT, Brain Spinal Other Craniopharyngioma, Brain Spinal Other Germ Cell Tumor, Brain Spinal Other Choroid Plexus Tumor, Brain Spinal Other All Other, Sarcoma Ewing Relapse, Sarcoma Osteosarcoma Relapse, Sarcoma Rhabdomyosarcoma Relapse, Neuroblastoma Relapse - Refractory, Liver Relapse - Refractory, Kidney Relapse - Refractory, Solid Tumors - All Other, Solid Tumor Retinoblastoma Relapse - Refractory, Solid Tumor Neurofibromatosis Sarcoma MPNST Relapse - Refractory, Solid Tumor Neurofibromatosis OPG Low Grade Glioma, Solid Tumor Melanoma Relapse - Refractory, Solid Tumor Germ Cell Tumor Relapse - Refractory

PURPOSE: This phase I trial studies the side effects and best dose of prexasertib in treating pediatric patients with solid tumors that have come back after a period of time during which the tumor could not be detected or does not respond to treatment. Checkpoint kinase 1 inhibitor LY2606368 may sto ...More

Contact Us

hospital

Adult Participants or Parents of Participants:

Cincinnati Children’s is involved in research because it is very important to understanding diseases and developing ways to prevent and treat health problems in children, as well as adults. Learn more about how you can help. Contact us at clinicalstudies@cchmc.org or 513-636-0098. Or, enroll in our database to be notified about future studies by completing an online sign up form.

Sponsors and Investigators:

The Office for Clinical and Translational Research at Cincinnati Children’s provides sponsors and investigators with comprehensive support services, research tools, personnel and facilities to conduct or facilitate pediatric and adult clinical research studies. Contact us at OCTR@cchmc.org or 513-636-0314.